Production (Stage)
Genocea Biosciences, Inc.
GNCAQ
$0.00
$0.000.00%
OTC PK
| 03/31/2022 | 12/31/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | 15.13% | -19.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.57% | 8.62% | |||
| Operating Income | -8.71% | -23.84% | |||
| Income Before Tax | -20.32% | -266.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.32% | -266.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.32% | -266.65% | |||
| EBIT | -8.71% | -23.84% | |||
| EBITDA | -7.54% | -26.29% | |||
| EPS Basic | -19.14% | -263.39% | |||
| Normalized Basic EPS | -9.95% | -294.14% | |||
| EPS Diluted | -19.14% | -263.39% | |||
| Normalized Diluted EPS | -9.95% | -294.14% | |||
| Average Basic Shares Outstanding | 1.02% | 0.85% | |||
| Average Diluted Shares Outstanding | 1.02% | 0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||